Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 2,020,000 shares of Artivion, Inc. (AORT) common stock, representing 4.3% of the class. The percentage is based on 47,374,939 shares outstanding as of October 31, 2025, as disclosed by the company.
The filers report shared voting power and shared dispositive power over 2,020,000 shares, with no sole voting or dispositive power. They certify the holdings were not acquired to change or influence control of Artivion.
AORT filed a Form 144 notice for a proposed sale of up to 6,393 shares of common stock with an aggregate market value of $287,685.00. The filing lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 11/14/2025, and the NYSE as the exchange.
The seller previously completed several sales in the past three months: 10,000 shares on 11/11/2025 for $461,800.00, 5,761 shares on 11/13/2025 for $264,189.66, and 2,960 shares on 11/10/2025 for $132,071.94. Shares outstanding were 47,374,939.
Artivion (AORT) disclosed an insider transaction by its VP, Chief Accounting Officer. On 11/13/2025, the officer sold 3,482 shares of common stock at $45.858 per share. According to the filing, the sale was executed to cover tax withholding triggered by the vesting of restricted stock units and “does not represent a discretionary transaction.”
Following this sell-to-cover transaction, the officer beneficially owned 141,380 shares, held directly.
Artivion, Inc. (AORT) reported an insider Form 4. The Chief Commercial Officer sold 6,563 shares of common stock at $45.858 on 11/13/2025 (Transaction code: S). According to the footnote, the shares were sold upon RSU vesting to cover tax withholding via a “sell to cover” and do not represent a discretionary transaction.
After the sale, the reporting person beneficially owned 198,842 shares, held directly.
Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.
Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.
Artivion, Inc. (AORT) insider transaction: SVP and General Counsel Jean F. Holloway reported the sale of 5,761 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon the vesting of restricted stock units to pay tax withholding obligations via a “sell to cover” and “does not represent a discretionary transaction.”
Following the sale, the reporting person beneficially owns 163,408 shares directly. This Form 4 reflects an administrative tax-related sale rather than an open‑market discretionary trade.
Artivion (AORT) insider transaction: Officer Marshall Stanton reported a sell-to-cover of 4,993 shares of common stock at $45.858 on 11/13/2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding obligations and did not represent a discretionary transaction.
Following the transaction, Stanton beneficially owns 56,641 shares directly. His role is listed as SVP, Clinical & MD Affair, and the filing was made by one reporting person.
AORT: A holder filed a Form 144 notice to sell 6,393 shares of common stock through Fidelity Brokerage Services, with an aggregate market value $285,575.31. The filing lists an approximate sale date of 11/14/2025 on the NYSE. Shares outstanding were 47,374,939.
The shares to be sold were acquired on 11/14/2025 via an option originally granted on 03/05/2019, with payment noted as cash. The filing also reports past 3‑month sales by John E. Davis: 3,373 shares on 11/10/2025 for $150,499.55 and 6,563 shares on 11/13/2025 for $300,968.02.
AORT received a Form 144 notice covering a proposed sale of 3,482 common shares. The filing lists an aggregate market value of $159,678.60, with an approximate sale date of 11/13/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired via restricted stock vesting on 11/10/2025 and 11/11/2025 in two equal tranches of 1,741 shares each, characterized as compensation. The filing also reports that Amy D. Horton sold 1,789 shares on 11/11/2025 for $79,823.21 in gross proceeds. Shares outstanding are listed as 47,374,939.
AORT filed a Form 144 notice for a proposed sale under Rule 144 by security holder Jean F. Holloway. The filing lists 5,761 shares of common stock to be sold, with an aggregate market value of $264,189.66, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025. Shares outstanding are shown as 47,374,939.
The shares to be sold were acquired via restricted stock vesting: 2,880 shares on 11/10/2025 and 2,881 shares on 11/11/2025, labeled as compensation. In the past three months, the filer reported sales of 10,000 shares on 08/25/2025 for $443,700.00, 2,960 shares on 11/10/2025 for $132,071.94, and 10,000 shares on 11/11/2025 for $461,800.00.